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Abstract
Purpose The aim of this study was to evaluate the fea-
sibility and toxicity of concurrent chemoradiotherapy
(CCRT) with S-1 in patients with locally advanced squa-
mous cell carcinoma of the head and neck (SCCHN) in
elderly cases and/or cases with comorbidity.
Methods Fifty eligible patients with stage III (15 cases)
or stage IV (35 cases) SCCHN were treated with CCRT.
Thirteen cases had an advanced age of over 75 years and
37 cases had comorbidity. Deﬁnitive radiotherapy was
delivered up to a total dose of 66–70.2 Gy. The patients
received two courses of oral S-1 (40 or 50 mg twice a day
[80 or 100 mg/day]) for 2 weeks followed by 1 week of
rest while receiving CCRT.
Results All the patients received the planned radiotherapy
and at least one course of S-1. Grade 3 mucositis occurred
in 20% of the patients (10/50). Grade 3 neutropenia
occurred in 12% (6/50) and leukocytopenia occurred in 6%
(3/50) of the cases. Pathologically, the complete response
rates were 93% in stage III and 54% in stage IV.
Conclusion Concurrent chemoradiotherapy with S-1 is a
safe, well-tolerated and effective regimen for locally
advanced SCCHN in elderly cases and/or cases with
comorbidity.
Keywords S-1  Chemoradiotherapy  Elderly cases 
Cases with comorbidity
Introduction
In an attempt to improve therapeutic results (survival or
function preservation), chemotherapy has been applied
before (neoadjuvant), with (concurrent), or after (adjuvant
or consolidation) conventional therapy (surgery and/or
radiotherapy). The rationale for concurrent chemoradio-
therapy (CCRT) is that chemotherapeutic agents may act as
radiation sensitizers in addition to contributing their own
anti-tumor effect [1]. Furthermore, effective chemotherapy
may control micrometastasis outside of the lesions treated
with radiotherapy. Some CCRT regimens have produced
an improvement in overall survival, disease-free survival,
locoregional control of the disease, or a decrease in distant
metastasis when examined in randomized trials where they
were compared with radiotherapy alone [2–4].
In terms of squamous cell carcinoma of the head and neck
(SCCHN), chemotherapy mainly consists of a platinum ana-
log(mainlycisplatin[CDDP])andthecontinuousintravenous
infusionof5-ﬂuorouracil(5-FU),especiallyintheneoajuvant
chemotherapy studies. On the other hand, the bolus admin-
istration of CDDP has been the most well-known regimen in
the CCRT studies [2–4]. Recently, docetaxel combined with
radiotherapy has been applied as a radio-sensitizer for fresh
HNSCC [5], and carboplatin with deﬁnitive radiotherapy has
been used for patients receiving NAC [6].
However, regimens with strong impacts cannot be
administered to patients of advanced age or with
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ease, since they entail severe toxicities like nephrotoxicity
(occurring with CDDP) or mucositis/cardiotoxicity
(occurring with the continuous intravenous infusion of
5-FU at high doses). Simultaneous combined therapy with
5-FU and radiotherapy in patients with SCCHN has been
reported to improve the therapeutic results when compared
with radiotherapy alone [7]. The radiosensitizing efﬁcacy
of 5-FU strongly depends on the continuous exposure of
the tumor cells to 5-FU for 8 h or more following irradi-
ation [8, 9]. Because of the short half-life of 5-FU, the drug
must be administered continuously to achieve an effective
level for prolonged tumor exposure.
S-1 is an oral anticancer agent comprising tegafur,
5-chloro-2,4-dihydroxypyridine,andpotassium oxonateata
molar ratio of1:0.4:1[10–12].Tegafurisaprodrugof 5-FU,
and 5-chloro-2,4-dihydroxypyridine enhances the serum
5-FU concentration through the competitive inhibition of
DPD, an enzyme responsible for 5-FU catabolism. Potas-
sium oxonate, a reversible competitive inhibitor of orotate
phosphoribosyl transferase, inhibits the phosphorylation of
5-FU in gastrointestinal tissue, reducing the diarrhea asso-
ciatedwith5-FU.InaphaseIItrialofadvancedandrecurrent
SCCHN(59 eligible cases), S-1 showed a high response rate
of 28.8% with acceptable toxicities [13]. The daily oral
administration of S-1 instead of intravenous 5-FU infusion
may be useful for reducing toxicity and producing a radio-
sensitizingeffect,resultinginananti-tumoreffect.However,
inconcurrentchemoradiotherapywithS-1,itisimpossibleto
avoid an increase in toxicities, compared with the single use
of S-1. The success of concurrent chemoradiotherapy
depends on a feasible and effective administration schedule
and S-1 dose that can be combined with radiotherapy.
Ascheduleof2 weeksofadministrationfollowedby1 week
of rest is more feasible than a schedule of 4 weeks of
administration followed by 2 weeks of rest over a 6-month
period for the administration of S-1 as an adjuvant chemo-
therapy for locoregionally advanced SCCHN [14].
When performing chemoradiation with S-1, the daily
administration of S-1 is essential; thus, a schedule of
2 weeks of S-1 administration followed by 1 week of rest
was used in this study.
Theprimaryoutcomesofinterestinthepresentstudywere
the feasibility and toxicity of CCRT with S-1, with tumor
response being of secondary interest. The intent was to be
abletorecommendcombinationtherapyforlocallyadvanced
SCCHN cases with advanced age and/or comorbidity.
Patients and methods
The eligibility criteria included histologically conﬁrmed
squamous cell carcinoma either of the larynx, oropharynx,
hypopharynx, or oral cavity; measurable or clinically
assessable disease; stage III or IV disease according to the
2002 staging system of the International Union Against
Cancer (UICC); disease limited to the head and neck region
(M0); an Eastern Cooperative Oncology Group (ECOG)
performance status of 2 or better; no prior radiotherapy or
chemotherapy; adequate bone marrow function, deﬁned as
a neutrophil count of [1,500 cells/mm
3 and a platelet
count of [100,000/mm
3; and adequate liver function,
deﬁned as a total bilirubin level of\1.25 times the upper
limit of normal (ULN), an aspartate or alanine amino-
transferase (AST or ALT) level of \2.5 ULN, and an
alkaline phosphatase level of \2.5 ULN. These criteria
included patients with renal dysfunction (creatinine clear-
ance rate between 40 and 60 mL/min), cardiovascular
disease, cerebral disorders, and/or advanced age
([75 years). Patients with active peptic ulcers were not
included in this study because S-1 induces mucositis,
which in turn aggravates peptic ulcers.
The criteria for surgical resection excluded patients with
invasion to the prevertebral muscle, invasion to the com-
mon or internal carotid artery (i.e., those showing positive
results on the artery occlusion test), or bulky metastasis in
the retro-pharyngeal lymph nodes. The pretreatment eval-
uation included a medical history, physical examination,
electrocardiogram and chest X-ray in all patients. The
laboratory evaluation consisted of a complete blood cell
count, urinalysis, and serum chemistry values, including
urea nitrogen, creatinine, calcium, albumin, AST, ALT,
alkaline phosphatase, and bilirubin. Computed tomography
(CT), magnetic resonance imaging (MRI) and neck ultra-
sonography analyses were performed in all the patients and
were used as an adjunct to the clinical evaluation to deﬁne
the tumor extent and the presence of nodal metastasis. To
check for distant metastasis, positron emission tomography
(PET), chest CT, abdominal ultrasonography, and bone
scintigraphy examinations were performed.
Two courses of S-1, 50 or 40 mg twice a day, admin-
istration with radiotherapy were given according to a
schedule of 2 weeks of administration followed by 1 week
of rest (one course). The daily dose of S-1 was reduced by
one dose level compared with the conventional adjuvant
setting, i.e., from 120 mg/day (60 mg, twice a day) to
100 mg/day (50 mg, twice a day) and from 100 mg/day
(50 mg, twice a day) to 80 mg/day (40 mg, twice a day).
The minimum dose of S-1 studied was 80 mg/day (40 mg,
twice a day). The S-1 was orally administered in the
morning 2 h before the start of daily radiotherapy and
again after the evening meal. To ascertain compliance with
oral administration into the patient, the medication was
checked daily by two or three nurses.
Radiotherapy was delivered 5 days a week using single
daily fractions of 1.8 or 2.0 Gy. Megavoltage radiation was
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123generated by a 6 MeV X-ray linear accelerator. The ﬁeld
size included the primary tumor and regional (cervical)
metastasis. After approximately 40 Gy, the patients were
reevaluated. The patients with an obvious clinical response
completed the radiotherapy with a total dose of between
66.0 and 70.2 Gy. In non-responders with resectable
tumors showing a progressive disease, surgery was rec-
ommended according to the physical condition of the
patient.
The patients were monitored for toxicity (medical
interview, physical examination, and complete blood cell
counts) during the treatment. Blood and urine chemistries
were performed twice a week. If the neutrophil count
dropped to\1,000 cells/mm
3 during CCRT, subcutaneous
G-CSF (100 lg/body/day) was injected.
Toxicity was assessed during the treatment and for
4 weeks after treatment using the 2003 Common Termi-
nology Criteria for Adverse Events, version 3.0 (CTCAE
v3.0). Unacceptable toxicity was deﬁned as follows: any
Grade 3 or higher non-hematological toxicity or Grade 4
hematological toxicity lasting more than 7 days or associ-
ated with fever, infection, or thrombocytopenia.
Although the major objective of this study was to
evaluate the feasibility and toxicity, an attempt was
made to evaluate the efﬁcacy of this drug combined with
radiotherapy in this patient population. In patients com-
pleting radiotherapy, the ﬁnal response at the primary
site and in the neck was evaluated 4–6 weeks later.
A complete response (CR) was deﬁned as the disap-
pearance of all clinical evidence of disease and negative
biopsy results for the primary site. The neck response
was deemed complete with the disappearance of any
adenopathy, as determined using ultrasonography. Fine-
needle aspiration cytology was performed when residual
nodal metastasis was suspected. A partial response (PR)
was deﬁned as a 50% or greater decrease in the product
of two perpendicular diameters of the primary and
regional tumors. The patients whose diseases did not
fulﬁll the criteria for a PR were deemed to have no
change (NC) or stable disease. The patients with less
than a CR of the primary and neck tumors were con-
sidered for planned surgery 4–8 weeks after the
completion of radiotherapy, and salvage surgery was
recommended when appropriate for local and/or regional
recurrence, if the patients could withstand surgical
treatments.
The overall and disease-speciﬁc survival rates were
calculated using the Kaplan–Meier method and were sta-
tistically analyzed using the generalized Wilcoxon test.
The study was approved by the local institutional review
boards. The patients were informed of the investigational
nature of this study and provided their written informed
consent.
Results
Patient characteristics
Between December 2002 and July 2007, 50 patients
received concurrent chemoradiotherapy as their primary
therapy for SCCHN. The patient characteristics are shown
in Tables 1 and 2. The median age was 68.0 years, while
that of the 13 cases with advanced age was 78.6 years.
According to the UICC staging system, 15 patients had
stage III and 35 patients had stage IV tumors. Twenty-one
cases had T4 tumors (42%), and 29 cases (58%) had N2 or
N3 tumors (Table 3). There were 35 resectable cases
(15 with stage III and 20 with stage IVA) and 15 unre-
sectable ones (stage IVB). Thirty-seven cases had
complications: 12 had a renal dysfunction (40\Ccr
\60 mL/min), 8 had respiratory disorders, 14 had car-
diovascular disorders, 6 had liver cirrhosis, 5 had cerebral
infarction, and 4 had other comorbidity.
Feasibility
Radiotherapy was completed to the planned dose of 66.0 or
70.2 Gy without early termination in all the patients (mean
dose: 68.4 Gy). Nevertheless, the chemotherapy regimen
was interrupted in 11 cases based on discussions with
radiation oncologists considering physical conditions of
patients: two cases with skin rash appearing 2 weeks after
the start of S-1 administration, four cases with neutropenia,
Table 1 Patients’ characteristics (1)
Characteristics No. of patients (n = 50)
Age: range (median) 38–88 (68) years
Sex
Male 47
Female 3
Stage
III 15
IV 35
Primary site
Larynx 9
Oropharynx 13
Hypopharynx 25
Oral cavity 3
Differentiation
Well 8
Moderately 25
Poorly 17
Resectability
Resectable 35
Unresectable 15
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123three cases with hepatic toxicity, and two cases with mu-
cositis during the second course of S-1 administration.
Three cases required a dose reduction of S-1 from 100 to
80 mg during the second course because of prolonged
hematological toxicity. All the cases received at least one
complete course of S-1 treatment (S-1 administration for
2 weeks) with radiotherapy. The completion rate of S-1
administration, as deﬁned by the protocol, was 72%.
Adverse events
The adverse events observed during treatment are listed in
Table 4. Grade 3 mucositis, neutropenia, leukocytopenia,
and ALT and AST elevations were observed in 10 cases
(20%), 6 cases (12%), 3 cases (6%) and 3 cases (6%),
respectively. During CCRT, 18 of the 50 cases (36%) had
difﬁculty eating with pain caused by mucositis and
required nutritional support and the administration of S-1
using a gastric tube. With regard to the frequency and
severity of adverse events, no signiﬁcant difference was
observed between patients with and those without a dete-
riorated Ccr. Fourteen patients had cardiovascular diseases,
but the worsening of symptoms was not observed in any of
the patients.
Response
In terms of CR rate according to T and N stagings, the rate
decreased as the T or N staging advanced (Table 5). The
CR rate in the primary site (42/50, 84%) was higher than
that of metastatic lymph nodes in the neck (29/39, 74%).
Of the 15 patients with stage III tumors, a CR was seen
in 14 (93%), while the CR rate in the stage IV patients (35
cases) was 54% (16/35) (Table 6). None of the patients
experienced disease progression while receiving CCRT.
After the completion of the chemoradiotherapy, 16 patients
had PR and 4 had NC. Four patients underwent operations
after receiving CCRT. Of the remaining patients, 5 had
unresectable tumors and 11 had resectable tumors but
Table 2 Patients’ characteristics (2)
Cases with advanced age (75 years\): 13 cases
Age: range (median) 76–88
(78.6) years
Cases with comorbidity: 37 cases
Renal dysfunction (40\Ccr\60 mL/min) 12 cases
Respiratory disorder 8 cases
Chronic obstructive pulmonary disease
Cardiovascular disorder 14 cases
Old myocardial infarction
Angina
Arrhythmia including atrial ﬁbrillation
Arteriosclerotic obliteration
Liver cirrhosis 6 cases
Old cerebral infarction 5 cases
Others (alcoholism, malignant hyperpyrexia,
epilepsy)
4 cases
Table 3 TN classiﬁcation
T stage
N stage T1 T2 T3 T4 Total
N0 0 0 7 4 11
N1a 1 4 3 2 10
N2a 0 0 0 0 0
N2b 0 2 2 9 13
N2c 1 4 3 6 14
N3 0 1 1 0 2
Total 2 11 16 21 50
Table 4 Adverse events (n = 50)
Grade 1/2 Grade 3 Grade 4
Hematological events
Leukocytopenia 15 (30%) 3 (6%) 0
Neutropenia 15 (30%) 6 (12%) 0
Anemia 13 (26%) 0 0
Thrombocytopenia 3 (6%) 0 0
Non-hematological events
Mucositis 24 (48%) 10 (20%) 0
Elevation of ALT, AST 4 (8%) 3 (6%) 0
Dermatitis 15 (30%) 1 (2%) 0
Skin rash 2 (4%) 0 0
Table 5 Response and CR rate according to T and N stagings
Response
T stage CR PR NC CR rate (%)
T1 (n = 2) 2 0 0 100
T2 (n = 11) 10 1 0 91
T3 (n = 16) 14 1 1 88
T4 (n = 21) 16 3 2 76
Total (n = 50) 42 5 2 84
N stage CR PR NC CR rate (%)
N1 (n = 10) 10 0 0 100
N2b (n = 13) 9 2 2 69
N2c (n = 14) 9 5 0 64
N3 (n = 2) 1 1 0 50
Total (n = 39) 29 8 2 74
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123could not undergo surgery because of their physical
condition.
Of the 14 CR cases with stage III tumors, 3 had recur-
rences (21%); the recurrence rate was 56% (9 cases) among
the 16 CR cases with stage IV tumors. Among these cases,
six had unresectable recurrences including two cases
showing lung metastases, three cases with resectable
recurrences underwent salvage surgery, and the remaining
three cases with resectable recurrences could not undergo
surgery because of their physical condition.
Survival
Although the number of cases was small and the follow-up
period was short, a preliminary attempt to evaluate the
outcome of the present study was made. The median fol-
low-up period for the surviving patients was 26 months
(range, 12–61 months). In Figs. 1 and 2, the 2-year dis-
ease-speciﬁc survival rate and the 2-year overall survival
rate were 92 and 75% in the stage III group and 38 and
29% in the stage IV group, respectively. The two groups
had signiﬁcantly different 2-year disease-speciﬁc and
overall survival rates (P\0.05). In terms of resectability,
the 2-year disease-speciﬁc survival rate and the 2-year
overall survival rates of unresectable cases, i.e., cases
showing stage IVB, were 33 and 32%, respectively. There
were no signiﬁcant differences compared to each survival
rate of resectable ones (64 and 48%; Figs. 3, 4).
Discussion
Recently, CCRT has been demonstrated to be highly
effective in increasing survival in patients with locally
advanced, especially unresectable, SCCHN in several
studies [15–17]; however, few recent studies have exam-
ined CCRT or neoadjuvant chemotherapy for locally
advanced SCCHN in patients with advanced age (over
75 years) or comorbidity [18, 19].
In terms of studies on CCRT for advanced SCCHN, a
bolus administration of CDDP alone with or without the
continuous infusion of 5-FU has been generally applied
[20]; however, CDDP administration requires hydration,
affecting heart function and inducing nephrotoxicity.
Additionally, the continuous infusion of 5-FU at a high
Table 6 Response according to staging and recurrent cases in CR
cases
Stage Response Recurrent cases
in CR cases
CR PR NC CR rate (%)
III (n = 15) 14 0 1 93 3/14 (21%)
IV (n = 35) 16 16 3 54 9/16 (56%)
Total (n = 50) 30 16 4 60 12/30 (40%)
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Fig. 1 Disease-speciﬁc survival. Kaplan–Meier estimates of disease-
speciﬁc survival in stage III and IV. Two-year disease-speciﬁc
survival rates were 92% in stage III and 38% in stage IV. There was a
signiﬁcant difference between the two groups (P = 0.039)
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Fig. 2 Overall survival. Kaplan–Meier estimate of overall survival in
stage III and IV. Two-year overall survival rates were 75% in stage III
and 29% in stage IV. There was a signiﬁcant difference between the
two groups (P = 0.039)
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Fig. 3 Disease-speciﬁc survival. Kaplan–Meier estimates of disease-
speciﬁc survival in resectable and unresectable cases. Two-year
disease-speciﬁc survival rates were 48% in resectable and 32% in
unresectable cases. There was no signiﬁcant difference between the
two groups (P = 0.598)
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2/day for 4 or 5 days) sometimes
induces cardiovascular disorders [21]. For these reasons,
the effective bolus administration of CDDP and/or the
continuous infusion of 5-FU combined with radiotherapy is
limited or prohibited in elderly patients with deteriorated
renal function and in cases with comorbidity like cardio-
vascular dysfunction. In fact, a decrease in creatinine
clearance with aging has been reported in patients with
head and neck cancer in Japan [22].
With regard to the roles of chemotherapeutic agents
combined with radiotherapy, a direct tumor-killing activity
in addition to a radio-sensitizing activity is superior to a
radio-sensitizing activity alone. Based on this concept, a
multi-agent chemotherapy consisting of CDDP, 5-FU,
methotrexate, and leucovorin or CDDP, 5-FU and doce-
taxel for advanced SCCHN cases with normal Ccr
([65 mL/min) and without comorbidity has been studied
in our institutes [23–25].
S-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) is a
dihydropyrimidine dehydrogenase (DPD)-inhibitory ﬂu-
oropyrimidine (DIF) that has produced the highest response
rate among many oral anticancer agents used against
unresectable advanced carcinomas in phase II studies [10].
S-1 is an oral anticancer agent comprising tegafur,
5-chloro-2,4-dihydroxypyridine, and potassium oxonate, in
a molar ratio of 1:0.4:1 [10–12]. The 5-chloro-2,4-dihydr-
oxypyridine enhances the serum 5-FU concentration by the
competitive inhibition of DPD, an enzyme responsible for
5-FU catabolism. In a phase II trial of advanced and
recurrent SCCHN (59 eligible cases), S-1 showed a high
response rate of 28.8%, with acceptable toxicities [13].
Generally, the dose of S-1 is determined according to
the body surface area (BSA) as follows: in a patient with a
BSA\1.25 m
2, 40 mg is administered twice a day
(80 mg/day); in a patient with a BSA of [1.25 m
2 but
\1.5 m
2, 50 mg is administered twice a day (100 mg/day);
and in a patient with a BSA[1.5 m
2, 60 mg is adminis-
tered twice a day (120 mg/day). In the present study, the
dose of oral S-1 was reduced by one dose level
(60 mg 9 2/day to 50 mg 9 2/day or 50 mg 9 2/day to
40 mg 9 2/day) because concurrent radiotherapy with S-1
at the doses used in the single agent treatment was thought
to induce severe mucositis in the head and neck. The
average single dose of S-1 per BSA was 29.5 mg/m
2 (25.3–
33.3 mg/m
2) in the present study. The results of a phar-
macokinetic study on S-1 showed that the plasma 5-FU
concentration after S-1 administration at an average single
dose of 35.9 mg/m
2 twice a day was similar to that during
the continuous intravenous infusion (CVI) of 5-FU at
300 mg/m
2/day, and the range of the plasma 5-FU level
after the administration of oral S-1 was narrower than that
during the CVI of 5-FU, since the inclusion of a DPD
inhibitor dampens the variation in the plasma 5-FU level
[26]. The time-to-peak plasma concentration of 5-FU has
been shown to reach a steady state 2–4 h after the
administration of S-1. Based on this previous pharmaco-
kinetic study, oral S-1 was administered 2 h before daily
radiotherapy in the present study; theoretically, this timing
should enable the plasma 5-FU concentration to peak and
sensitize the tumor cells to radiation. Oral S-1 adminis-
tration at a reduced dose was thought to allow a high Cmax
and a greater area under the curve (AUC) of plasma 5-FU
than the venous infusion of 5-FU at a dose of 250 mg/m
2
during one course of chemotherapy with S-1 for 2 weeks
[27]. Furthermore, there have been several reports regard-
ing the sensitizing effect of S-1 on radiotherapy [28, 29].
Harada et al. reported that S-1 increases the in vivo radio-
response of tumor xenografts derived from oral cancer
cells, and that 5-FU has an ability to sensitize the in vitro
radio-response of these cells by suppressing the activation
of Akt/PKB, an important survival signal. Nakata et al.
have shown that S-1 treatment enhances the response of 5-
FU-resistant human colon carcinoma cells to radiotherapy
through the down-regulation of thymidine synthase, an
enzyme involved in tumor resistance to 5-FU and radiation.
In terms of the optimal schedule of CCRT with S-1 for
oral squamous cell carcinoma, a schedule of 2 weeks of
administration followed by 1 week of rest has been shown
to cause fewer toxicities than a schedule of 4 weeks of
administration followed by 2 weeks of rest, similar to our
results in an adjuvant setting examining the use of S-1 for
SCCHN [14, 30].
With regard to CCRT with S-1, Tsuji et al. reported that
the recommended dose of S-1 was 80 mg/body/day
(40 mg, twice a day) for cases with early glottic cancer
(T2N0)[ 31]. The completion rate in the present study, as
deﬁned by the protocol, was 72% (36/50). Thirty-nine of
the 50 cases (78%) received CCRT with two courses of S-1
administration, although dose reduction was needed in
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Fig. 4 Disease-speciﬁc survival. Kaplan–Meier estimates of disease-
speciﬁc survival in resectable and unresectable cases. Two-year
disease-speciﬁc survival rates were 64% in resectable and 33% in
unresectable cases. There was no signiﬁcant difference between the
two groups (P = 0.458)
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cases with an advanced age and/or complications, CCRT
with S-1 at the planned dose seems to be feasible. Since
most cases with SCCHN have advanced diseases, 100 mg/
body/day might be indispensable for advanced SCCHN
cases with a high BSA.
Based on the above-mentioned pharmacokinetic results,
oral S-1 administered twice a day at a reduced dose was
thought to be capable of both direct tumor cell killing and
radio-sensitization, similar to the CVI of 5-FU.
In the present study, mucositis was the most common
adverse effect, i.e., Grade 3 mucositis occurred in 20% of
the patients. This rate was higher than the results of a study
on oral cancer in a younger patient group without comor-
bidity [30] and the phase I study on CCRT with S-1 for early
glottic cancer [31]. Aging, comorbidity, and the radiation
ﬁeld might inﬂuence the severity of mucositis. The rate of
Grade 3 mucositis in the present study seems lower com-
pared to CCRT with the common bolus administration of
CDDP [2, 4]. Some reasons are considered; ﬁrst, S-1 is an
oral agent resulting in a weaker radiosensitizing effect
compared to CDDP. Second, in the present study nutrition
support using a gastric tube was performed as soon as
possible when the hyperemic mucosa was found during
CCRT, because all the patients were elderly and/or had
comorbidity. Similar to mucositis, neutropenia was also
observed frequently, and Grade 3 neutropenia and leuko-
penia occurred in 12 and 6% of the patients, respectively. In
an adjuvant setting study examining feasibility and safety,
no patients with grade C3 neutropenia or mucositis were
observed among cases receiving 2 weeks administration of
S-1 followed by a 1-week rest [14]. The adverse events in
the present study might have been induced by the combined
treatment of radiotherapy with S-1. On the other hand, none
of the patients in the present study experienced diarrhea,
possibly because of the dose reduction.
CCRT with S-1 produced a high compete response rate
(60%) in advanced cases with advanced age and/or
comorbidity. Compared with a previous study examining
CCRT with carboplatin (CBDCA) and UFT for SCCHN
cases with a poor PS (2 and 3), the CR rate of CCRT with
S-1 was similar to that of CCRT with CBDCA plus UFT
(61%) [18]; however, the study on CCRT with CBDCA
plus UFT included cases with nasopharyngeal carcinoma (9
out of 62 cases), which is sensitive to CCRT, and a smaller
numbers of cases with stage IV disease (35 out of 62 cases)
and with unresectable lesions (15 out of 62 cases, data not
included in the published manuscript). It is difﬁcult to
compare CCRT with S-1 to that with CDDP in terms of
effectiveness, toxicity, survival and quality of life, because
37 of 50 cases had comorbidity including apparent renal
dysfunction. Furthermore 12 of the 13 elderly patients
showed low Ccr rate with less than 75 mL/min. These
patients are not able to renal toxicity induced by CDDP and
massive hydration before and after CDDP administration.
Compared to the previous reports regarding CCRT with
CDDP in locally advanced SCCHN in not elderly patients
without comorbidity [2, 4], the effectiveness and survival
rates of CCRT with S-1 seem to be slightly worse.
In conclusion, the present regimen of concurrent che-
moradiotherapy with S-1 for advanced SCCHN cases with
an advanced age or with comorbidity is feasible and well-
tolerated, suggesting this regimen to be beneﬁcial. These
results warrant further investigation in terms of their effect
on patient outcome and function, and a phase II random-
ized controlled study examining CCRT with S-1 or weekly
docetaxel has been started in locally advanced SCCHN
patients with the same baseline patient characteristics.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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